Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Limitations Of The Commercially Available Gene Expression Test In Predicting Cutaneous Squamous Cell Carcinoma Metastasis And Clinical Outcomes.

Home
Limitations Of The Commercially Available Gene Expression Test In Predicting Cutaneous Squamous Cell Carcinoma Metastasis And Clinical Outcomes.

Related Concept Videos

Related Experiment Video

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma

Joel L Sax¹, Christopher D McFarland¹, Bryan T Carroll²

¹Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Journal of the American Academy of Dermatology

|May 18, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study critically evaluates the DecisionDx-SCC genetic test, finding potential dataset biases and inconsistencies in accuracy metrics. These findings underscore the need for rigorous validation of clinical genetic tests for reliable patient care.

Keywords:

cancer biology clinical genetics cutaneous squamous cell carcinoma dermatology gene expression genomics

More Related Videos

Experimental Metastasis Assay

Experimental Metastasis Assay

Published on: August 24, 2010

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Related Experiment Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Experimental Metastasis Assay

Experimental Metastasis Assay

Published on: August 24, 2010

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Area of Science:

Oncology
Genetics
Molecular Diagnostics

Background:

Clinical genetic testing is essential for medical decision-making.
Cutaneous squamous cell carcinoma (cSCC) is a significant health concern.
Accurate genetic profiling is crucial for effective cSCC management.

Purpose of the Study:

To critically evaluate the DecisionDx-SCC genetic test by Castle Biosciences.
To identify potential dataset biases, gene panel selection issues, and accuracy metric reporting.
To provide insights into challenges within the clinical genetic testing landscape.

Main Methods:

Independent analysis of DecisionDx-SCC 40-GEP test data.
Comparison with clinical genetic testing standards and national cSCC prevalence rates.
Gene ontology analysis of 34 genes for cSCC associations and evaluation of accuracy metrics.

Main Results:

The DecisionDx-SCC dataset exhibited a higher metastasis prevalence than the national average.
Fifteen out of 34 analyzed genes showed known associations with cSCC.
Inconsistencies were observed in the reporting of accuracy metrics, particularly for moderate and high-risk categories.

Conclusions:

The analysis of DecisionDx-SCC suggests potential biases and ambiguities in its current form.
There is a critical need for systematic validation of such genetic tests.
Ensuring precision and dependability in genetic testing is paramount for optimal patient care.